| scholarly article | Q13442814 |
| P50 | author | Anna Vassall | Q78838744 |
| P2093 | author name string | H Cox | |
| G J Fox | |||
| M Pai | |||
| S Sahu | |||
| F Varaine | |||
| J P Cegielski | |||
| D W Dowdy | |||
| E A Kendall | |||
| L Mabote | |||
| P2860 | cites work | Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis | Q23909492 |
| Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? | Q26740240 | ||
| Evolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapy | Q27016579 | ||
| Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade | Q28071919 | ||
| Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective | Q28074085 | ||
| Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection | Q28087385 | ||
| Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study | Q28273981 | ||
| Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis | Q28476120 | ||
| Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients | Q28482730 | ||
| Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru | Q28540737 | ||
| Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK | Q28544800 | ||
| Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial | Q28548037 | ||
| Prospects for Tuberculosis Elimination | Q29392153 | ||
| The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling | Q30244104 | ||
| Tuberculosis innovations mean little if they cannot save lives | Q33627409 | ||
| Isoniazid-resistant tuberculosis: a cause for concern? | Q33820505 | ||
| Tuberculosis among health care workers in KwaZulu-Natal, South Africa: a retrospective cohort analysis | Q34169209 | ||
| Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis | Q34285599 | ||
| Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients--a retrospective cohort study | Q34603793 | ||
| Lessons from Africa: developing a global human rights framework for tuberculosis control and prevention | Q34694347 | ||
| Increasing transparency in partnerships for health--introducing the Green Light Committee | Q34976025 | ||
| Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa | Q35072895 | ||
| Towards tuberculosis elimination: an action framework for low-incidence countries | Q35344151 | ||
| Target product profile of a molecular drug-susceptibility test for use in microscopy centers | Q35588123 | ||
| Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. | Q35662072 | ||
| Whole Genome Sequencing Shows a Low Proportion of Tuberculosis Disease Is Attributable to Known Close Contacts in Rural Malawi | Q35693533 | ||
| Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review. | Q36024119 | ||
| Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study | Q36286134 | ||
| Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. | Q36355254 | ||
| Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis | Q36377090 | ||
| Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. | Q36386227 | ||
| Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance | Q36497854 | ||
| Global Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient Needs | Q36617085 | ||
| Multidrug-resistant tuberculosis in children: evidence from global surveillance | Q37137678 | ||
| Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project | Q37270722 | ||
| Principles for designing future regimens for multidrug-resistant tuberculosis. | Q37398037 | ||
| Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis | Q37473011 | ||
| A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis | Q37954377 | ||
| Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews | Q38013804 | ||
| The history of antiretroviral therapy and of its implementation in resource-limited areas of the world | Q38019330 | ||
| Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. | Q38065028 | ||
| F-A-S-T: a refocused, intensified, administrative tuberculosis transmission control strategy | Q38414238 | ||
| Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis | Q38465643 | ||
| Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement | Q38674895 | ||
| Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis | Q38886442 | ||
| Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis | Q39014367 | ||
| Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation | Q39129067 | ||
| Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. | Q39297351 | ||
| Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa | Q39381653 | ||
| Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance | Q39632030 | ||
| Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis | Q40043590 | ||
| Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa | Q40180199 | ||
| Real-Time Sequencing of Mycobacterium tuberculosis: Are We There Yet? | Q40290488 | ||
| Molecular diagnosis of tuberculosis: we need solutions that span the healthcare value chain. | Q40454569 | ||
| Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis | Q40878891 | ||
| Six-Month Response to Delamanid Treatment in MDR TB Patients | Q41941864 | ||
| Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. | Q42281128 | ||
| Delay in commencing treatment for MDR TB at a specialised TB treatment centre in KwaZulu-Natal | Q44869539 | ||
| The molecular epidemiology of tuberculosis in New York City: the importance of nosocomial transmission and laboratory error | Q46884262 | ||
| Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis | Q46959941 | ||
| Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study | Q47202008 | ||
| Can social interventions prevent tuberculosis?: the Papworth experiment (1918-1943) revisited | Q47406971 | ||
| Antibiotic development pipeline slows to a trickle | Q50112545 | ||
| WHO's new end TB strategy. | Q50995464 | ||
| Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. | Q52629914 | ||
| Pan-tuberculosis regimens: an argument against. | Q53697549 | ||
| Pan-tuberculosis regimens: an argument for. | Q53697551 | ||
| Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible? | Q53701413 | ||
| Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations. | Q53766519 | ||
| Tailoring a time-bomb. Inadvertent genetic engineering. | Q54443311 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 535-546 | |
| P577 | publication date | 2019-05-01 | |
| P1433 | published in | International Journal of Tuberculosis and Lung Disease | Q15767020 |
| P1476 | title | What will it take to eliminate drug-resistant tuberculosis? | |
| P478 | volume | 23 |
| Q89538546 | Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives |
| Q92974903 | Drug-resistant tuberculosis: Progress towards shorter and safer regimens |
| Q92802035 | Isoniazid-resistant tuberculosis: A problem we can no longer ignore |
| Q90129922 | Management of drug-resistant tuberculosis |
| Q91620177 | Projecting the impact of variable MDR-TB transmission efficiency on long-term epidemic trends in South Africa and Vietnam |
Search more.